TRAIL R3/TNFRSF10C Antibody MAB6302 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemTRAIL R3/TNFRSF10C Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price $579.00Supplier Page View Company Product Page
Catalog NumberMAB6302
NCBI Gene AliasesDCR1, TRID, CD263, LIT, DCR1-TNFR, TRAIL-R3, TRAILR3
ApplicationsFlow Cytometry,CyTOF-ready
IsotypeIgG1
TargetTRAIL R3/TNFRSF10C
Clone90906
HostMouse
ReactivityHuman,Rat
Quantity500 ug (also 25 ug)
Conjugate/TagUnconjugated
NCBI Full Gene NameTNF receptor superfamily member 10c
ClonalityMonoclonal
PurityProtein A or G purified from hybridoma culture supernatant
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution
ImmunogenMouse myeloma cell line NS0-derived recombinant human TRAIL R3/TNFRSF10C, Met1-Ala221, Accession # O14798
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS

Specifications/Features

Available conjugates: Available conjugates: Unconjugated

Specificity: Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) TRAIL R2, rhTRAIL R1, or rhTRAIL R4 is observed.

Sizes Available: 500 ug (also 25 ug)

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of GlioblastomaMolecules (Basel, Switzerland)December 14, 2021Krishna Moorthy N, Seifert O, Eisler S, Weirich S, Kontermann RE, Rehm M, Fullstone G.anti-TRAILR1/TNFRSF10A (MAB347, 1:100), mouse anti-TRAILR2/TNFRSF10B (MAB6311, 1:100), mouse anti-TRAILR3/TNFRSF10C (MAB6302, 1:100), mouse anti-TRAILR4/TNFRSF10D (MAB633, 1:100), purified mouse IgG1 (1:100) and purified mouse

(2) Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacyScientific reportsNovember 17, 2020Yoo JD, Bae SM, Seo J, Jeon IS, Vadevoo SMP, Kim SY, Kim IS, Lee B, Kim S.with the following four anti-human TRAIL receptor antibodies: MAB347 (anti-DR4), MAB6311 (anti-DR5), MAB6302 (anti-DcR1), and MAB633(anti-DcR2) (R&D Systems, Minneapolis, MN, USA)70. For cell binding analyses,

(3) Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexesThe Journal of biological chemistryJune 6, 2014Neumann S, Hasenauer J, Pollak N, Scheurich P.

(4) TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cellsAnticancer researchFebruary 1, 2014Tang XJ, Lu JT, Tu HJ, Huang KM, Fu R, Cao G, Huang M, Cheng LH, Dai LJ, Zhang L.

(5) TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cellsCancer gene therapySeptember 1, 2012Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL.

(6) Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)Journal of cellular physiologyFebruary 1, 2010Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P.

(7) Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patientsBloodOctober 29, 2009Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, Quendler H, Kohrgruber N, Stingl G.

(8) Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanismsMolecular cancer therapeuticsAugust 1, 2008Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK.

(9) P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cellsOncogeneJuly 10, 2008Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC.

(10) Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cellsJournal of cellular biochemistryMay 15, 2008Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C.

(11) A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosisCell death and differentiationApril 1, 2008Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M.

(12) Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosisMolecular cancer therapeuticsDecember 1, 2007Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM.

(13) Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cellsThe Journal of investigative dermatologyOctober 1, 2007Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Dürkop H, Sterry W, Eberle J.

(14) HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinomaOncogeneJuly 7, 2005Singh TR, Shankar S, Srivastava RK.

Be the First to Write a Review!

TRAIL R3/TNFRSF10C Antibody

TRAIL R3/TNFRSF10C Antibody

TRAIL R3/TNFRSF10C Antibody

TRAIL R3/TNFRSF10C Antibody from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (14)

Reviews

TRAIL R3/TNFRSF10C Antibody from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map